Figure S4. The CLDN7 promoter DNA methylation site, cg00072720, was associated with poor overall survival time while in hypermethylated status. (JPG 470 kb
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Table S5. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Figure S2. Immunohistochemistry staining analysis of CLDN11 in nine paired NPC tissues with higher m...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S4. Correlation between CLDN7 promoter DNA methylation site (cg00072720) and clinicopathologic...
Figure S5. Gene-set enrichment analysis is used to identify the pathways in two different CLDN7 mRNA...
Table S5. Gene-set enrichment analysis between high- and low- CLDN7 group in Kidney clear cell carci...
Table S3. Correlation between CLDN7 expression and 653 clinicopathological features in 534 ccRCC pat...
Table S1. The clinicopathological features of 120 ccRCC patients from Peking University First Hospit...
Figure S4. Distribution of hyper- and hypomethylated CpGs in patients with or without specific genom...
Figure S2. Copy number variation (CNV) analysis. CNV analysis of twelve chromosome regions previousl...
Figure S5. Correlations between number of hypomethylated CpGs and number of genetic aberrations and ...
Table S8. Top 20 most significant GO Terms for GeneIDs either hyper- or hypomethylated in M0-P and M...
Table S4. Cox’s proportional hazard regression analysis for cancer specific survival (CSS) in 115 cc...
Figure S1. Single nucleotide polymorphism (SNP) analysis. SNP analysis of 65 genotyping probes on th...
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Table S5. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Figure S2. Immunohistochemistry staining analysis of CLDN11 in nine paired NPC tissues with higher m...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S4. Correlation between CLDN7 promoter DNA methylation site (cg00072720) and clinicopathologic...
Figure S5. Gene-set enrichment analysis is used to identify the pathways in two different CLDN7 mRNA...
Table S5. Gene-set enrichment analysis between high- and low- CLDN7 group in Kidney clear cell carci...
Table S3. Correlation between CLDN7 expression and 653 clinicopathological features in 534 ccRCC pat...
Table S1. The clinicopathological features of 120 ccRCC patients from Peking University First Hospit...
Figure S4. Distribution of hyper- and hypomethylated CpGs in patients with or without specific genom...
Figure S2. Copy number variation (CNV) analysis. CNV analysis of twelve chromosome regions previousl...
Figure S5. Correlations between number of hypomethylated CpGs and number of genetic aberrations and ...
Table S8. Top 20 most significant GO Terms for GeneIDs either hyper- or hypomethylated in M0-P and M...
Table S4. Cox’s proportional hazard regression analysis for cancer specific survival (CSS) in 115 cc...
Figure S1. Single nucleotide polymorphism (SNP) analysis. SNP analysis of 65 genotyping probes on th...
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Table S5. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Figure S2. Immunohistochemistry staining analysis of CLDN11 in nine paired NPC tissues with higher m...